According to plaintiff lawyers in a new talc injury trial commencing in Missouri, Johnson & Johnson worked to increase sales of its talc powder products by specifically targeting African-American women — women who already face a higher cancer risk relating to talc use. The lawsuit is being brought on behalf of three African-American women who died of ovarian cancer after long term use of Johnson & Johnson’s talcum powder products. [Read more…]
On May 26, 2017, the fourth pelvic mesh injury case against Johnson & Johnson to reach trial ended with a $2.16 million verdict in favor of Sharon Beltz, a Pennsylvania woman whose lawsuit alleged that J&J subsidiary Ethicon’s surgical mesh product led to permanent injuries including chronic pain. [Read more…]
A new study from the Children’s Environmental Health Network (“CEHN”) Healthy Kids Initiative testing 69 pregnant women, reveals that exposure to the widely-used herbicide known as glyphosate accumulates in pregnant women and leads to unfavorable birth outcomes.
Talcum powder has been used by women and girls for decades in what was thought to be a harmless method of absorbing moisture as a drying and anti-chafe agent. However, a U.S. jury verdict linking regular use of talcum powder to a women’s wrongful death from ovarian cancer highlights the potentially fatal risks from ongoing use of talcum powder products. [Read more…]
A Missouri state court jury awarded nearly $71 million dollars on Thursday to a woman claiming she developed ovarian cancer due to using Johnson & Johnson’s talc-containing personal hygiene products on her genitals for decades, who accused the company of not warning consumers about the products’ health risks in order to protect profitable brands. [Read more…]
As reported by the New York Times, women with little or no other cancer risk factors appear to be developing ovarian cancer as a result of their use of talcum powder as a drying and anti-chafe agent. [Read more…]
According to a new study from Northwestern Medicine published in the journal Obstetrics and Gynecology, 22% of a series of high-risk medical devices approved for use in women between 2000 and 2015 won FDA approval based on flawed safety data. [Read more…]
The U.S. Food and Drug Administration (FDA) has reclassified the surgical mesh device utilized for transvaginal repair of pelvic organ prolapse (“POP”) and other conditions in women as a high-risk (class III) product. Previously, the agency classified the product as moderate-risk (class II). [Read more…]